Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.91 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.91 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.91 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | THRB | P10828 | 3/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.44 |
| ▸ | GABRD | O14764 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL33937 | 1.00 | — | — | |
| Glycine SCHEMBL142869 | 0.96 | — | — | |
| Glycine SCHEMBL28646078 | 0.96 | GLRA1 (0.83) | GLRA1SLC6A9OR51E2GABRR1LMNA | |
| Glycine SCHEMBL29262734 | 0.96 | GLRA1 (0.83) | GLRA1SLC6A9OR51E2GABRR1LMNA | |
| Glycine SCHEMBL15842974 | 0.96 | — | — | |
| Glycine SCHEMBL28179941 | 0.96 | — | — | |
| Glycine SCHEMBL28873025 | 0.96 | — | — | |
| Glycine SCHEMBL1627850 | 0.96 | — | — | |
| Glycine SCHEMBL2116443 | 0.95 | — | — | |
| Glycine SCHEMBL3640989 | 0.95 | GLRA1 (1.00) | GLRA1SLC6A9OR51E2GABRR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117203337-A | Method for treating muscular dystrophy | 萨勒普塔医疗公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4157252-A1 | METAL DI-AMINO ACID CHELATES OR METAL TRI-AMINO ACID CHELATES | Balchem Corporation (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-4157820-A1 | METAL DI-AMINO ACID CHELATES OR METAL TRI-AMINO ACID CHELATES | Balchem Corporation (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20210371374-A1 | METAL DI-AMINO ACID CHELATES OR METAL TRI-AMINO ACID CHELATES | SYRACUSE UNIVERSITY | 2021-12-02 | — | — | US | disclosed |
| US-20210369768-A1 | METAL DI-AMINO ACID CHELATES OR METAL TRI-AMINO ACID CHELATES | SYRACUSE UNIVERSITY | 2021-12-02 | — | — | US | disclosed |
| CN-113143901-A | Magnesium composition and use thereof | 纽罗森特里亚股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-112638383-A | Long-term evening administration of rasemiptan for migraine prophylaxis | 伊莱利利公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-107412217-B | Magnesium composition and use thereof | 纽罗森特里亚股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20170049811-A1 | MODIFIED SINGLE DOSE, MICROPLEGIC APPROACH TO CARDIOPLEGIA FOR ADULT HEART | BERRY CATHERINE E (US) | 2017-02-23 | — | — | US | disclosed |
| WO-2015168540-A1 | A MODIFIED SINGLE DOSE, MICROPLEGIC APPROACH TO CARDIOPLEGIA FOR THE ADULT HEART | BERRY CATHERINE E (US) | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371374-A1 | METAL DI-AMINO ACID CHELATES OR METAL TRI-AMINO ACID CHELATES | AADAT, DNPEP, SLC30A6 | GLRA1 559/4885SLC6A9 81/4885OR51E2 4645/4885 |
| US-20210369768-A1 | METAL DI-AMINO ACID CHELATES OR METAL TRI-AMINO ACID CHELATES | AADAT, DNPEP, SLC30A6 | GLRA1 559/4885SLC6A9 81/4885OR51E2 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.